PBYI

Over the past six months (April - October 2026), Puma Biotechnology experienced several stock-impacting events. In Q1 2026, the company reported a net loss but noted a year-over-year increase in NERLYNX demand and raised its full-year 2026 revenue and net income guidance. Q2 2026 saw strong results, with revenue of $56.5 million and GAAP EPS of $0.16, both beating estimates, and NERLYNX sales increasing 27.6% sequentially. The company also became debt-free and further raised its full-year guidance, leading to the stock reaching a new 52-week high in October 2026. Analyst ratings were updated in August 2026, with TD Cowen increasing its price target to $6.00, Wall Street Zen upgrading to a 'strong-buy', and Weiss Ratings raising its rating. In September 2026, Puma Biotechnology announced the initiation of its ALISCA®-Lung2 Phase II trial for alisertib. However, Director Alessandra Cesano sold 62,150 shares of the company's stock. Overall, the stock surged 95% to $9.97 by October 2026 from $4.73 in November 2025, and rallied 19.4% in the three months leading up to June 2026 due to improving NERLYNX demand and a raised revenue outlook.